FIRST: Roche wins DCGI nod for Atezolizumab to treat small-cell lung cancer
"Atezolizumab is the first cancer immunotherapy to receive approval from DCGI in India for the first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC) when given in combination with chemotherapy," Roche India said in a statement.
New Delhi: Drug firm Roche India on Thursday said it has launched Atezolizumab used for the treatment of small-cell lung cancer in India after getting a nod from Drugs Controller General of India.
"Atezolizumab is the first cancer immunotherapy to receive an approval in India for the first line treatment of extensive-stage small cell lung cancer (ES-SCLC) when given in combination with chemotherapy," Roche India said in a statement.
The cancer immunotherapy harnesses the person's immune system to combat cancer more effectively for better results, it added.
Read Also: CDSCO committee tells Roche to submit Phase III clinical trial data of blood cancer combo drug
"Roche is committed to bringing to India all the innovations being developed in its pipeline, to benefit patients," Lara Bezerra, chief purpose officer at Roche Products (India) said. Launching Atezolizumab is an important step for small cell lung cancer patients in India, she added.
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at firstname.lastname@example.org. Check out more about our bureau/team here